Calculated Under Revenue Guidance In Effect Before Topic 606 was AbbVie’s largest revenue line in the Dec 2018 quarter, bringing in $8.36B of $8.31B (101%).
| Initial Application Period Cumulative Effect Transition | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 |
|---|---|---|---|---|
| Calculated Under Revenue Guidance In Effect Before Topic 606 | $7.89B | $8.29B | $8.27B | $8.36B |
| Difference Between Revenue Guidance In Effect Before & After Topic 606 | $43.00M | -$13.00M | -$34.00M | -$55.00M |
| Total | $7.93B | $8.28B | $8.24B | $8.31B |
Humira was AbbVie’s largest revenue line in the Jun 2018 quarter, bringing in $5.19B of $8.28B (63%).
| Products and Services | Mar 2012 | Jun 2012 | Sep 2012 | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humira | $4.70B | $4.71B | $5.19B | ||||||||||||||||||||
| H U M I R A | — | — | — | ||||||||||||||||||||
| Imbruvica | $688.00M | $762.00M | $850.00M | ||||||||||||||||||||
| Hcv | $276.00M | $919.00M | $973.00M | ||||||||||||||||||||
| Viekira | — | — | — | ||||||||||||||||||||
| All Other | $181.00M | $201.00M | $151.00M | ||||||||||||||||||||
| Other Products | — | — | — | ||||||||||||||||||||
| Tri Cor Trilpix | — | — | — | ||||||||||||||||||||
| Niaspan | — | — | — | ||||||||||||||||||||
| Androgel | $147.00M | $130.00M | $128.00M | ||||||||||||||||||||
| Andro Gel | — | — | — | ||||||||||||||||||||
| Lupron | $201.00M | $219.00M | $223.00M | ||||||||||||||||||||
| Synagis | $116.00M | $321.00M | $44.00M | ||||||||||||||||||||
| Kaletra | $85.00M | $73.00M | $91.00M | ||||||||||||||||||||
| Dyslipidemia Products | — | — | — | ||||||||||||||||||||
| Synthroid | $191.00M | $182.00M | $193.00M | ||||||||||||||||||||
| Creon | $215.00M | $209.00M | $219.00M | ||||||||||||||||||||
| Sevoflurane | $100.00M | $106.00M | $113.00M | ||||||||||||||||||||
| Zemplar | — | — | — | ||||||||||||||||||||
| Norvirember | — | — | — | ||||||||||||||||||||
| Duodopa | $94.00M | $103.00M | $108.00M | ||||||||||||||||||||
| Total | $7.00B | $7.93B | $8.28B |
Pull AbbVie's revenue breakdown - every line it reports, for every period - into your own models, spreadsheets and apps with the Business Quant Segments API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/segments?series=Revenue&ticker=ABBV&dimension=Quarter&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/segments"
params = {"series": "Revenue", "ticker": "ABBV", "dimension": "Quarter", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/segments?series=Revenue&ticker=ABBV&dimension=Quarter&api_key=YOUR_API_KEY");
const data = await res.json();